UPDATE : Thursday, July 9, 2020
상단여백
Court rejects Kolon’s appeal over Invossa license revocation by Jeong Sae-im 2019-09-25 11:18
FDA recommends Kolon to remanufacture Invossa’s second fluid by Jeong Sae-im 2019-09-23 15:32
Drug firms uncertain about pricing of quadrivalent flu vaccines by Jeong Sae-im 2019-09-23 14:52
‘Galderma Korea ran background checks on unionized workers’ by Jeong Sae-im 2019-09-19 15:18
Regulator delays decision on delisting Kolon TissueGene by Jeong Sae-im 2019-09-18 14:27
라인
Biotech startups seek IPO via ‘growth potential exception’ policy by Jeong Sae-im 2019-09-17 11:26
Chong Kun Dang wins patent suit against Novartis over immunosuppressant by Jeong Sae-im 2019-09-11 15:16
Daewoong to test botulinum toxin Nabota for hair loss by Jeong Sae-im 2019-09-11 13:56
Novartis withdraws suit against Ahngook’s generic drug by Jeong Sae-im 2019-09-10 15:38
Invossa victims furious at government, Kolon for ‘doing nothing’ by Jeong Sae-im 2019-09-09 15:47
라인
Nobel laureate Honjo anticipates best combo in immunotherapies by Jeong Sae-im 2019-09-06 16:29
Yuhan to expand biz scope to central nervous system disease by Jeong Sae-im 2019-09-06 14:56
SK goes global by developing new drugs, conducting CDMO biz by Jeong Sae-im 2019-09-03 14:58
Hanmi, Daewoong among 20 innovative top-tier drugmakers in Asia Pacific by Jeong Sae-im 2019-09-02 17:33
JW Pharmaceutical’s hyperlipidemia drug Livalo safe from diabetes risk by Jeong Sae-im 2019-08-30 14:49
라인
Change in licensing-out contract may be bad sign for Intron Biotechnology by Jeong Sae-im 2019-08-30 14:47
Antidiabetic DPP-4 inhibitors mark double-digit sales growth by Jeong Sae-im 2019-08-29 11:24
Sales of new gastric acid blocker K-Cab top ₩10 billion by Jeong Sae-im 2019-08-28 13:26
Invossa victims, Kolon shareholders demand apology, compensation by Jeong Sae-im 2019-08-27 15:40
HLB to test rivoceranib+Lonsurf in colon cancer by Jeong Sae-im 2019-08-27 15:39
여백
여백
여백
Back to Top